<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538863</url>
  </required_header>
  <id_info>
    <org_study_id>INS-06-007</org_study_id>
    <nct_id>NCT00538863</nct_id>
    <nct_alias>NCT00589004</nct_alias>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain</brief_title>
  <official_title>Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for
      the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their
      persistent cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label multi-center study of the safety of fentanyl sublingual spray as a
      treatment for breakthrough cancer pain. The study medication was administered under the
      tongue as a simple spray and could be self-administered by patients or assisted by their
      caregivers. In addition to safety, there was a questionnaire to assess satisfaction with the
      study medication.

      Subjects could enter this study by 1 of 2 routes:

        -  De novo subjects who meet the inclusion criteria and none of the exclusion criteria at
           the Screening Visit were enrolled into the Open-label Titration Period of the study.
           Upon successful completion of the titration period, patients entered the Open-label
           Maintenance Period.

        -  All patients who successfully completed the Double-blind Randomization Period and the
           Final Visit of study INS-05-001 (NCT00538850) were eligible to enter the Open-label
           Maintenance Period of this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients That Experienced 1 or More Adverse Events</measure>
    <time_frame>Baseline to end of the study (up to 116 days)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Fentanyl sublingual spray titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl sublingual spray maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl sublingual spray</intervention_name>
    <description>Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg</description>
    <arm_group_label>Fentanyl sublingual spray titration</arm_group_label>
    <arm_group_label>Fentanyl sublingual spray maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects who have completed the Double-blind Period and Final Visit of protocol
        INS-05-001(NCT00538850), Multicenter Randomized Double-blind Trial of Fentanyl Sublingual
        Spray for the Treatment of Breakthrough Cancer Pain are eligible for participation in this
        open-label extension study.

        All de novo subjects must meet all of the following criteria to be eligible for
        participation in the study:

          1. Male or female, &gt; 18 years of age.

          2. Diagnosis of cancer.

          3. Opioid treatment. Patients who are treated with opioids are defined as those patients
             who are taking at least 60 mg of oral morphine/day, at least 25 µg of transdermal
             fentanyl/hour, at least 30 mg of oxycodone/day, at least 8 mg of oral
             hydromorphone/day or an equianalgesic dose of another opioid for &gt; 7 days for
             cancer-related pain.

          4. Experience persistent pain related to the cancer or its treatment of moderate or
             lesser intensity in the 24 hours prior to assessment by a verbal rating scale at the
             Screening Visit.

          5. Experience on average 1 to 4 breakthrough cancer pain episodes per day usually at
             least partially controlled by supplemental medication of at least 5 mg
             immediate-release morphine or an equivalent short-acting opioid (eg, oxycodone,
             hydrocodone, or codeine with acetaminophen).

          6. Able to evaluate pain relief, assess medication performance, report adverse events
             (AEs), report use of the study drug or supplemental medication (a caregiver may
             provide the subject the medication).

          7. Able and willing to give informed consent.

          8. Women of childbearing potential must have a) a negative urine pregnancy test, b) not
             be breast feeding and c) agree to practice a reliable form of contraception.

        Exclusion Criteria:

          1. Intolerable side effects to opioids or fentanyl.

          2. Rapidly increasing/uncontrolled pain.

          3. A history of major organ system impairment or disease, that in the Investigator's or
             his/her designee's opinion could increase the risk associated with the use of opioids.

          4. Uncontrolled hypertension (systolic blood pressure [BP] &gt; 180 mm Hg or diastolic BP &gt;
             90 mm Hg on 2 occasions at least 6 hours apart) despite antihypertensive therapy, or
             has a history of hypertensive crisis within the past 2 years.

          5. A recent history (within the past 2 years) of transient ischemic attacks, neural
             vascular disease, stroke, or cerebral aneurysms.

          6. Serum creatinine, ALT or AST that is greater than 3 times the upper limit of normal.

          7. Diagnosis of sleep apnea.

          8. Brain metastases with signs or symptoms of increased intracranial pressure.

          9. Inability to assess pain or response to pain medications for any reason, including
             psychiatric disorder, concurrent medical disorder, or concomitant therapy.

         10. Has used methadone within 14 days of the Screening Visit.

         11. Received an investigational study product(s) within 30 days of the Screening Visit.

         12. Use of monoamine oxidase (MAO) inhibitors within 14 days of the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Dillaha, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Insys Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winfield</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flat Rock</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lemoyne</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Sam Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nasik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2007</study_first_posted>
  <results_first_submitted>September 11, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2013</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The number of patients in the fentanyl sublingual spray maintenance group includes 179 patients who completed the fentanyl sublingual spray titration period of the study plus 90 patients who entered the study directly in the maintenance period.</recruitment_details>
      <pre_assignment_details>Five patients who completed the titration period did not start the maintenance period due to failure to determine a dose in the titration period (n=1), withdrawal from the study (n=3), and adverse event (n=1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fentanyl Sublingual Spray</title>
          <description>In the titration period, patients were titrated upward to a maximum dose of 1600 µg fentanyl sublingual spray. In the maintenance period, patients received a dose of 100 to 1600 µg fentanyl sublingual spray determined in a previous study (INS-05-001, NCT00538850) or in the titration period of the current study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Titration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269">Five participants who completed the titration period did not start the maintenance period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The total number of patients enrolled in the study is 319.</population>
      <group_list>
        <group group_id="B1">
          <title>Fentanyl Sublingual Spray</title>
          <description>In the titration period, patients were titrated upward to a maximum dose of 1600 µg fentanyl sublingual spray. In the maintenance period, patients received a dose of 100 to 1600 µg fentanyl sublingual spray determined in a previous study (INS-05-001, NCT00538850) or in the titration period of the current study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="319"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Titration Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Titration period - Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titration period - Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance period - Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance period - Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients That Experienced 1 or More Adverse Events</title>
        <time_frame>Baseline to end of the study (up to 116 days)</time_frame>
        <population>Safety population: All patients who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl Sublingual Spray Titration</title>
            <description>Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl Sublingual Spray Maintenance</title>
            <description>Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients That Experienced 1 or More Adverse Events</title>
          <population>Safety population: All patients who received study medication.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were followed to resolution, an outcome had been reached, stabilization, or the event was otherwise explained regardless of whether the subject was still participating in the study (up to 150 days).</time_frame>
      <desc>Safety population: All patients (n=319) who received study medication. The number of patients in the fentanyl sublingual spray maintenance group includes 179 patients who completed the fentanyl sublingual spray titration period of the study plus 90 patients who entered the study directly in the maintenance period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fentanyl Sublingual Spray Titration</title>
          <description>Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl Sublingual Spray Maintenance</title>
          <description>Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urostomy complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Real failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Larry Dillaha, M.D., Chief Medical Officer</name_or_title>
      <organization>Insys Therapeutics, Inc.</organization>
      <phone>602-910-2617</phone>
      <email>ldillaha@insysrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

